Chloé Shard

DHODH is the key target of the KDM4 inhibitor QC6352 in glioblastoma stem cells

Abstract Histone lysine demethylase 4 (KDM4) enzymes are frequently overexpressed in cancer and are considered to be promising therapeutic targets. QC6352, which is widely used as a best-in-class KDM4 chemical probe, shows potent antitumor activity across cancer models. Using com...

FAP+ pericyte-like cells promote monocyte differentiation into tumor-associated macrophages in glioblastoma

Abstract Glioblastoma (GBM) is a highly aggressive primary brain tumor characterized by profound immunosuppression that facilitates tumor progression and promotes therapeutic resistance. Fibroblast activation protein (FAP), a recognized theranostic target in multiple cancers, is...